ABSTRACT: We present results of tests with recombinant Lactococcus lactis that produce and secrete heterologous antimicrobial peptides with activity against Gram-negative pathogenic Escherichia coli and Salmonella. In an initial screening, the activities of numerous candidate antimicrobial peptides, made by solid state synthesis, were assessed against several indicator pathogenic E. coli and Salmonella strains. Peptides A3APO and Alyteserin were selected as top performers based on high antimicrobial activity against the pathogens tested and on significantly lower antimicrobial activity against L. lactis. Expression cassettes containing the signal peptide of the protein Usp45 fused to the codon-optimized sequence of mature A3APO and Alyteserin were cloned under the control of a nisininducible promoter PnisA and transformed into L. lactis IL1403. The resulting recombinant strains were induced to express and secrete both peptides. A3APO-and Alyteserin-containing supernatants from these recombinant L. lactis inhibited the growth of pathogenic E. coli and Salmonella by up to 20-fold, while maintaining the host's viability. This system may serve as a model for the production and delivery of antimicrobial peptides by lactic acid bacteria to target Gram-negative pathogenic bacteria populations.
T
here is growing concern worldwide that extensive use of antibiotics is resulting in the development of antibiotic resistance among pathogenic bacteria. In particular, antibiotic overuse in livestock feeds compromises the effectiveness of current therapies via dissemination of antibiotic resistance genes to both disease-causing and commensal microorganisms. 1, 2 Over 80% of the antibiotics produced in the United States are administered in swine, poultry, and cattle farming. In addition to their intended use as therapeutics, antibiotics are administered throughout the life of food-producing animals, even in the absence of infection, to promote animal growth and improve feed efficiency. 3, 4 These growth-promoting antibiotics are applied at subtherapeutic concentrations, establishing the conditions for resistance to antibiotics to develop. Alarmingly, many of the antibiotics used in agriculture have also been listed as critically important for human health by the World Health Organization. Humans depend on many of these same antibiotics as a first line of defense against pathogens like Escherichia coli O157:H7, Salmonella typhimurium, Staphylococcus aureus, Streptococcus, and Pseudomonas aeruginosa.
5 Therefore, there is a pressing need for new therapeutic agents with activity against pathogenic bacteria and alternative technologies for application in agriculture, such that front line therapeutics can be reserved for effectively treating infections in humans.
One promising alternative to traditional antibiotic molecules are antimicrobial peptides (AMPs). AMPs are small, often positively charged, peptides with high antimicrobial activity.
The activity of AMPs can be broad, efficiently acting on many Gram-positive and Gram-negative bacteria species. There are, however, AMPs with very specific activity, targeting one particular bacteria species or even a specific subspecies of a given genus. 6−11 The current production, purification, and delivery methods available for these peptides have numerous limitations. For example, solid state peptide synthesis and peptide production and purification from cell cultures are both costly and timeconsuming. 11−13 Additionally, the subsequent targeted delivery of active amounts of these compounds can be challenging. Generally, AMPs cannot be administered orally as they are quickly degraded before they are able to reach their target. AMPs cannot be administered systemically either, as they are rapidly identified and targeted for clearance by the immune system before they can reach the site of infection. 11 Moreover, high peptide concentrations are required to achieve a therapeutic effect which would be cost-prohibitive and would, more importantly, cause severe toxic side effects. Taken together, these limitations have thus far stifled the development of AMP-based therapeutics.
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In recent years, probiotic bacteria have emerged as useful tools for effectively boosting overall human and animal health. 14 Probiotics are typically Gram-positive, bile-resistant, bacteria that either colonize or transiently inhabit the gastrointestinal (GI) tract of a host. When administered in adequate amounts, they confer health benefits by improving nutrient absorption and decreasing the relative abundance of potentially pathogenic bacteria.
15, 16 Lactic acid bacteria (LAB), which include microbes in the genera Lactobacillus and Lactococcus, and Bifidobacterium are currently the bacteria most commonly employed as probiotics. 14, 16 A number of probiotic bacteria are currently in use as nutritional supplements for humans and animals. 17−23 In addition, recombinant LAB are also significant therapeutic delivery vectors. They are presently being tested as candidates for the delivery of therapeutics inside the GI tract of humans for the treatment of inflammatory bowel syndrome and Crohn's disease. 24−26 Although the therapeutic promise of modified LAB is yet to be realized in these cases, there have been numerous demonstrations that LAB can be used as vehicles to deliver proteins inside the GI tracts of hosts.
Here, we report the results of experimental efforts to design, build, and characterize AMP production and delivery systems founded on probiotic bacteria. Our approach is based on Lactococcus lactis, a noninvasive and nonpathogenic LAB, generally recognized as safe by the FDA, with probiotic properties that are amenable to heterologous protein overexpression. 27, 28 Since L. lactis is able to survive in the GI tract of both humans and animals, this bacterium is an excellent candidate to deliver health benefits to the targeted host organism. 28 Over the last two decades several genetic tools have been developed for L. lactis, 29−32 making it suitable to engineer as an efficient cellbased protein expression factory. 31,33−35 On the basis of these attributes, L. lactis may be an ideal vehicle for producing and delivering AMPs to the site of GI infection. 36 The systems that we report constitute L. lactis strains that have been engineered to inducibly express and secrete the AMPs Alyteserin-1a and A3APO, both peptides that are active against Gram-negative pathogenic Escherichia coli and Salmonella strains. Our systems have been engineered with the intention of future application as an alternative to antibiotics in agriculture.
■ RESULTS AND DISCUSSION
Motivated by the current state of antibiotic overuse and the rapid emergence of bacterial strains with resistance to antibiotics molecules, the overall goal of this work was to engineer a LAB strain to inducibly express and secrete AMPs with high activity against important Gram-negative pathogens. In summary, this was achieved by first screening AMPs for high activity against pathogenic E. coli and Salmonella strains and low activity against LAB. Gene-encoding peptides that displayed the most favorable activity were then included in expression cassettes for use in L. lactis. In the following, we detail how we (1) selected the AMPs of interest, (2) engineered L. lactis to express the heterologous peptides, and (3) tested the recombinant expression systems. To our knowledge, this is one of the first works in which LAB have been engineered to express and secrete AMPs that are specifically active against Gram-negative pathogens.
Screening of AMPs with Activity against Gram-Negative Bacteria. Recently discovered AMPs that have been introduced into clinical practice largely display activity against Gram-positive organisms while being ineffective against Gram-negative bacteria. 37 This is due in part to the unique cell wall and membrane structure of these two classes of bacteria. 38, 39 However, there are a few exceptional AMPs that show high specific activity against Gram-negative bacteria. 40, 41 To select top candidate AMPs to use in our study, we initially searched the literature for functional peptides fulfilling the following requirements: (1) lack of post-translational modifications and disulfide bonds, (2) activity against Gram-negative bacteria at low concentrations (≤500 μg/mL), and (3) no or significantly less activity against Gram-positive bacteria, in particular against the L. lactis host LAB. From this first screen, numerous candidates were chosen (data not shown) and chemically synthesized as described in Methods. The minimum inhibitory concentration (MIC) of the synthetic peptides was evaluated against a panel of pathogenic strains of E. coli and Salmonella and against L. lactis.
Two peptides, Alyteserin-1a (Alyteserin) and A3APO, emerged as promising candidate AMPs. Alyteserin was previously identified in the secretions on frog skin, while A3APO was discovered in a synthetic peptide library screen. 42, 43 The MIC of pure Alyteserin was 500 μg/mL against indicator E. coli and Salmonella strains. Additionally, L. lactis remained viable despite treatment with up to 1 mg/mL Alyteserin (Figure 1a) .
Inhibition of E. coli by A3APO was observed only at a concentration of 1 mg/mL. However, Salmonella growth was inhibited by 30 μg/mL Alyteserin, reducing viability through the highest concentration tested (1 mg/mL). Similarly, L. lactis growth was not inhibited with the different A3APO concentrations tested (Figure 1b) .
The two AMPs chosen in this study did not require posttranslational modifications for activity. The heterologous production of proteins that require post-translational modifications to be active can be problematic when using LAB as hosts. There are several examples where recombinant peptides that required post-translational modifications were being produced at high concentrations but had low specific activity. 44 This has been attributed to a variety of causes, such as nonefficient disulfide bond formation, problems in protein folding, and protein aggregation. 45 Once the two candidate peptides were identified, L. lactis was engineered to express Alyteserin and A3APO. Details of this process are presented in Methods. The resulting L. lactis were cultured to express and secrete the peptides. The cell-free supernatants containing these AMPs were isolated and their effect on E. coli and Salmonella growth and viability were assessed, as also described in Methods.
Construction of Recombinant L. lactis Strains for AMP Production. Lactococcus lactis strain IL1403 was engineered to express the AMPs Alyteserin and A3APO as detailed in Methods. Briefly, the codon-optimized nucleotide sequences of both peptides were synthesized by GeneArt and fused to the Usp45 secretion signal peptide sequence (SP usp45 ). 46 The expression cassettes were cloned downstream of the nisin inducible promoter, PnisA, from plasmid pMSP3545, 29 resulting in recombinant vectors pMS-Alys and pMS-A3APO, respectively. L. lactis IL1403 was transformed with both recombinant vectors, and the resulting L. lactis (pMS-A3APO) and L. lactis (pMS-Alys) strains, as well as the control L. lactis strain (L. lactis containing the empty pMSP3545 vector), were cultured to express and secrete each AMP. The AMPcontaining supernatants (SN) (AMP-SNs: Alys-SN, A3APO-SN, and C-SN for supernatants containing AMPs Alyteserin, A3APO, and the control supernatant lacking AMPs, respectively) were collected as described in Methods.
Growth of pathogenic and nonpathogenic E. coli strains was assessed in medium containing these AMP-SNs, while only pathogenic Salmonella strains were tested. In all cases, AMPSNs diluted 7:3 with LB were inoculated with each indicator strain and growth was monitored spectrophotometrically at 600 nm for 15 h.
Peptide Production and Secretion. qPCR was performed to determine the transcript levels of Alysteserin and A3APO genes upon induction. A3APO transcript increased by over 100-fold upon induction, while Alyteserin mRNA increased by 30-fold (data not shown). To confirm the production of recombinant Alyteserin and A3APO by L. lactis, a His-tag sequence was fused to the C-terminus of both genes. The induced cultures were centrifuged and 2 fractions were collected: the cell pellet and the cell-free supernatant. The cellpellet was lysed, as described in Methods, obtaining a cell lysate. The cell-free supernatants were treated with ammonium sulfate to 50% saturation to precipitate and concentrate the proteins. The crude supernatants, the ammonium sulfate and the cell-lysate fractions were subjected to dot blotting and immunological detection using Anti-His (C-terminal) antibodies. No signal was detected in any of the fractions obtained from the L. lactis control strain. A signal was detected in the crude supernatant samples from the AMP producing L. lactis. Increased signal was detected upon concentration with ammonium sulfate and in the cell-lysate fractions (data not shown). Although this confirms the presence of AMPs in the supernatants, it illustrates that a significant amount of peptide still remains inside the cells. Similar observations have also been observed with other recombinant peptides fused to the Usp45 signal peptide. 47 The protein size and the particular combination of signal peptide and mature protein are factors that may be limiting the secretion of the peptides.
E. coli Growth Inhibition by Alyteserin Produced by L. lactis. As shown in Figure 2 , Alys-SN inhibited growth of E. coli strains. Culture titer was assessed starting at 30 min postinoculation, and culture density was monitored by OD 600 10−15 h postinoculation. Prior to the 6 h time point, E. coli cultures treated with Alys-SN and C-SN were not statistically different (data not shown). However, different culture concentrations were observed beginning 6 h postinoculation (Figure 2a) , and this differential growth pattern was maintained through 15 h (Figure 2b ). Upon treatment with Alys-SN, culture concentrations were reduced by over 20-fold relative to those treated with C-SN at 6 h postinoculation and maintained a density at or less than this value through the 15 h incubation period. The same trends were found with all E. coli strains tested. Growth rates for E. coli, as shown in Table 1 , were calculated based on culture densities 10−15 h postinoculation. There was no significant E. coli growth when treated with Alys-SN during this time, and the cultures never achieved exponential growth. Thus, Alys-SN effectively inhibited E. coli growth during the 15 h culture period.
In contrast, there was no change in E. coli culture concentration when strains were cultured with A3APO-SN (data not shown). The MIC value for synthetic A3APO against E. coli strains was 1 mg/mL (Figure 1) , and it is reasonable that the concentration of active peptide is lower than this in tested supernatant samples.
Salmonella Growth Inhibition by Alyteserin-1a and A3APO Produced by L. lactis. Alys-SN and A3APO-SN inhibited growth of pathogenic S. typhimurium and S. infantis, as shown in Figure 3a . As before, the culture titer was assessed beginning 30 min postinoculation and culture density was monitored by OD 600 from 10 to 15 h. By 2 h postinoculation, a differential titer between cultures treated with Alys-SN and A3APO-SN was observed (Figure 3a ). Relative to culture growth with C-SN treatment, growth of S. infantis treated with Alys-SN was reduced by about one-half, while S. typhimurium was reduced by 10-fold. Moreover, A3APO-SN reduced the culture density of S. infantis by over 20-fold relative to C-SN, while S. typhimurium culture density was reduced by 4-fold. The inhibition of Salmonella by Alys-SN was maintained through 15 h, while culture density with A3APO-SN was the same as C-SN by 10 h postinoculation (Figure 3b) . At 15 h postinoculation, the Alys-SN maintained Salmonella culture densities at only 25% relative to the same strains treated with the C-SN. These trends were consistent across both the S. infantis and S. typhimurium strains tested. The strong activity shown by A3APO-SN against Salmonella is consistent with the significantly lower MIC value observed (30 μg/mL) for synthetic A3APO peptide against Salmonella.
As shown in Table 1 , growth rates for Salmonella were calculated based on culture densities 10 to 15 h postinoculation.
In contrast to what was observed with E. coli, there was significant Salmonella growth in the presence of Alys-SN, and the cultures achieved exponential growth. However, growth rates were reduced by 15% relative to cultures grown in C-SN during this time. Additionally, although the densities of the Salmonella cultures grown in A3APO-SN were significantly reduced at earlier time points, relative to C-SN, no differences were observed at 10 h after inoculation.
Improving Active Peptide Production. Currently, the factors that most significantly improve the antimicrobial activity of Alyteserin and A3APO produced by recombinant L. lactis are difficult to determine. We postulate that the use of SP usp45 to produce and secrete these peptides is likely to be one such factor as there are significant context dependencies between a secretion peptide and the molecule for which they are driving secretion. 48 Peptide translation, targeting the Sec-dependent protein to the membrane, the translocation process itself, and the peptide's subsequent processing by a signal peptidase likely represent the major bottlenecks for efficient translocation and thus production of heterologous proteins. 49 Since there are no good prediction methods for determining the right combination of secretion peptide and target protein to achieve a high protein production system, 44, 50 screening for a more efficient secretion peptide and protein combinations for overproduction and secretion may still further improve active peptide secretion. 49, 51 Several strategies have been used in this direction. Using different signal petides, 44 modifying the amino acids of the N-terminus of the signal peptide 52 or adding a propeptide between the signal peptide and the mature protein may help increase peptide secretion. 53 Further experiments must be performed in order to maximize the secretion of AMPs and further increase the antimicrobial activity of the supernatants. Improper protein folding may also account for compromised antagonistic activity. Thus, the use of chaperones, increasing specific peptide activity through rounds of mutagenesis, and increasing peptide gene copy number are approaches currently being pursued to improve these expression systems. 54 
■ SUMMARY
In this study, we report that L. lactis can be used to produce and secrete the antimicrobial peptides Alyteserin-1a and A3APO with sufficient activity to inhibit pathogenic E. coli and Salmonella strains while maintaining the host's viability. Previous studies have reported the production and secretion of AMPs by recombinant L. lactis. 44, 45, 55 However, these peptides have frequently displayed antimicrobial activity against Grampositive bacteria but either no or poor activity against Gramnegative indicators. 56, 57 While the activity of A3APO and Alyteserin in the supernatants of recombinant L. lactis is still not at the level of many small molecule antibiotics, to our knowledge this is the first time that a synthetic or animal-origin AMP has been produced by L. lactis with activity against Gramnegative bacteria pathogens. This opens up possibilities for the design of new synthetic peptides and the engineering of known AMPs to improve their antimicrobial activity and spectrum of action. Although beyond the scope of the present work, it is interesting to identify the peptide sequence and structure features that are responsible for the specificity against Gramnegative bacteria. With such features known, engineering of new peptides may be rationalized, as was recently accomplished with Alyteserin. 58 An important hypothesis that has been tested with relative success for various classes of antimicrobial peptides is that they act by binding and permeabilizing the membranes of bacteria. 59 It is well-established that the inner lipid bilayer membranes differ substantially between Grampositive and Gram-negative bacteria, mostly in their content of phosphoethanolamine (PE).
60 PE changes the electrostatic and the mechanical properties of lipid bilayers. An understanding of exactly how is currently lacking but may in the future guide engineering peptides that preferentially bind and insert into the membranes of Gram-negative bacteria.
Lactic acid bacteria are bile-resistant, generally considered safe to consume organisms that may take hold in the gastrointestinal tract of animal or human hosts. As such, they can be considered as promising delivery vehicles for AMPs to the site of gastrointestinal infections. By making and delivering peptides to the site of E. coli or Salmonella infections, AMPproducing organisms may circumvent previous limitations of the short half-lives that are characteristic of AMPs and the high production and purification costs also associated with peptides.
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■ METHODS Synthetic Peptide Synthesis. The synthetic AMPs used in this study (Table 2) were synthesized by solid-phase methods at the BioMedical Genomics Center at the University of Minnesota (20 mg aliquots at 99% purity).
Bacterial Strains and Growth Conditions. The bacteria used in this study are listed in Table 3 . L. lactis IL1403 was cultured at 30°C in M17 broth (Oxoid Ltd., Basingstoke, U.K.) supplemented with 0.5% (w/v) glucose (GM17). The E. coli and Salmonella strains were grown in LB broth (Fisher Scientific, Fair Lawn, NJ, USA) at 37°C, with shaking. Agar plates were made by the addition of 1.5% (wt/vol) agar (Oxoid) to the liquid media. When necessary, erythromycin (Sigma Chemical Company, St. Louis, MO) was added to the cultures at 200 and 5 μg/mL, for E. coli and L. lactis, respectively.
Molecular Biology. The amino acid sequences of the peptides Alyteserin and A3APO (Table 2) were used as templates for design of the synthetic genes. The nucleotide sequences for each peptide were then based on the preferred codon usage for expression by L. lactis. The nucleotide sequences of the synthetic expression cassettes contained the Usp45 signal peptide nucleotide sequence (SP usp45 ) (Table 4) and a 5′-nucleotide extension containing a NcoI restriction site at the N-terminus. It also included and a 3′-nucleotide extension with the stop codon (TAA) and the XbaI restriction site. All synthetic genes were supplied by GeneArt (Life Technologies, Paisley, U.K.).
Molecular cloning techniques were performed according to Sambrook et al., 61 and all DNA restriction enzymes were supplied from New England BioLabs (Beverly, MA) and used Construction of Expression Vectors. The plasmids and synthetic genes used in this study are listed in Table 4 . The SP usp45 :Alyteserin and SP usp45 :A3APO containing NcoI-XbaI fragments were obtained from the digestion of the Geneart vectors pMK-RQ-Alys and pMK-RQ-A3APO, respectively. These fragments were inserted into plasmid pMSP3545, in frame with the strong inducible Nisin A (PnisA) promoter, obtaining plasmids pMS-Alys and pMS-A3APO, respectively.
Protein Production. Recombinant L. lactis were induced to produce both AMPs upon reaching an OD 600 of 0.5, using nisin A (Sigma) at a final concentration of 25 ng/mL as the inducer. Cell-free culture supernatants were obtained by centrifugation of cultures at 12000g at 4°C for 10 min and filtering through 0.2 μm pore-size filters (Whatman Int. Ltd., Maidstone, U.K.). Supernatants were stored at −20°C until use.
Peptide Transcript Quantification by qPCR. A3APO and Alyteserin production was induced, as described above. Three hours postinduction mRNA was isolated using the RNeasy kit and RNAprotect Bacteria Reagent (Qiagen). cDNA libraries were made from each RNA sample using SuperScript II reverse transcriptase (Life Technologies) as directed, and qPCR was performed using Brilliant III Ultra-Fast SYBR Green QPCR Master Mix (Agilent Technologies) as directed using the internal ROX dye as a reference. Primers Alys-qPCR-F (CGTTGTCAGGTGTTTACGCTGGTTT) and Alys-qPCR-R (CGTTTAATTAGCAACATGAGCAGCAA) were designed to amplify a 95 bp product of Alyteserin gene. Primers A3APO-qPCR-F (TTTTAATGTCTACAGTGATACTTTCTGCTGC) and A3APO-qPCR-R (ATACGTTTAACGAACTGGACGTGG-TG) were designed to amplify a 122 bp product of A3APO gene. Primers Tuf-qPCR-F (GCGTTCTGGAGTTGGGATGT) and Tuf-qPCR-R (CCTCTTGAGCGAATACGATT) were designed to amplify a 149 bp product of the elongation factor Tu gene (tuf), which was used as an internal control. Relative transcript increases upon induction were calculated for both AMPs from CT values.
Production and Immunodetection of His-Tagged Proteins. To confirm the production of recombinant Alyteserin and A3APO by L. lactis using immulogical technics, a 6xHis-tag sequence was fused to the C-terminus of the cloned genes. Primers SPUsp45-F (ACTCATCATGAAAAAAAAGATTAT-CTCAGC) and A3APO-HIS-R (GATCTAGATTAGTGA-TGGTGATGGTGATGACCACCACGAACTGGACGTGGT-GG) were used in a PCR reaction to amplify a BspHI/XbaI 180 bp fragment containing SP usp45 :A3APO fused to a C-terminal 6xHis-tag (fragment SP usp45 :A3APO:HIS). Primers SPUsp45-F and Alys-HIS-R (GATCTAGATTAGTGATGGTGATGG-TGATGACCACCATTAGCAACATGAGCAGC) were used in a PCR reaction to amplify a BspHI/XbaI 192 bp fragment containing SP usp45 :Alys fused to a C-terminal 6xHis-tag (fragment SP usp45 :Alys:HIS). Fragments SP usp45 :A3APO:HIS and SP usp45 :Alys:HIS were digested with the indicated restriction enzymes and inserted into pMSP3545 and digested with NcoI and XbaI. The ligation mixtures were used to transform L. lactis IL1403 competent cells. The plasmid derivatives pMS-Alys:HIS and pMS-A3APO:HIS, respectively, were checked by PCR and sequencing of the inserts.
L. lactis IL1403 (pMSP3545), L. lactis IL1403 (pMS-A3APO:HIS), and L. lactis IL1403 (pMS-Alys:HIS) strains were grown in 100 mL of GM17 medium and induced with nisin A at an OD 600 of 0.5, as previously described. Three hours after induction, the cultures were centrifuged at 12000g at 4°C for 15 min. 50 mL of the supernatants (SN) were stored at −20°C until use, while the remaining 50 mL were subjected to precipitation with ammonium sulfate (50%) and resuspended in 1 mL phosphate-buffered saline (PBS) (AS-SN). The cell pellets where washed with PBS and resuspended in 2 mL of ice-cold PBS. Cells were lysed in a Fast-prep apparatus (Biospec) using 0.1 mm glass beads and 6 cycles of 45 s (speed 6.0), with cooling intervals of 45 s on ice. The unbroken cells, cell debris, and glass beads were separated from the cell lysate (CL) by centrifugation at 16100g at 4°C for 30 min. Twenty microliters of SN, AS-SN, and CL were spotted into a Amersham Hybond-P PVDF membrane (GE Healthcare), as indicated by the manufacturer. After transfer of the proteins onto the membranes, a dot blots analysis was performed using the Chemiluminescent Western Breeze kit (Invitrogen, Carlsbad, CA). For detection of Alys:His and A3APO:His, an anti-His (C-term) mouse monoclonal antibody (Invitrogen) was used as recommended by the manufacturer.
Bioassays for Antimicrobial Activity. MICs of the synthetic AMPs were determined in triplicate by a liquid growth inhibition microdilution assays in flat-bottom sterile polypropylene 96-well plates (Maxisorp, Nunc, Roskilde, Denmark), in a final volume of 150 μL. The bacteria were diluted 2% in fresh media and grown to an OD 600 = 0.5 ± 0.05 (OD 600 = 1 ≈ 10 9 cells/mL). The cells were diluted 50-fold to 10 7 cells/mL in fresh media. The AMP stocks were serially diluted (150 μL/well) in liquid growth media in a 96-well plate, covering a concentration range of 1000 μg/mL −1 ng/mL. Briefly, 150 μL of the serially diluted AMPs were inoculated with 5 μL of the bacterial strains to achieve a final indicator concentration of 3 × 10 5 cells/mL. For each strain, a row with no peptide was included as growth control, and for each test, a row of medium-only wells was included as a sterility control. Plates were then incubated at 37°C for 16−20 h without shaking, and growth inhibition was assessed measuring OD 600 using a microplate reader (SpectraMax Plus384; Molecular Devices, Sunnyvale, CA). MICs were identified as the lowest antimicrobial concentration, where the OD 600 just exceeds that of the control.
The loss of cell viability was monitored to determine the antimicrobial activity of the supernatants from the recombinant L. lactis strains. Briefly, 0.3 mL of fresh medium, individually inoculated with the target strains, was added to tubes containing 0.7 mL of the supernatants, to reach a final concentration of 1 × 10 3 cells/mL. As a control, a supernatant sample from the L. lactis strain containing only the expression vector pMSP3545 (C-SN) was used. Tubes were incubated at 37°C with agitation. Samples were taken at 30 min, 2 and 6 h, and the number of colony forming units per mL (CFU/mL) was determined by plating 25 μL on LB agar plates. The plates were incubated at 37°C for 16 h, and the number of viable cells was assessed by counting CFUs. Additionally, the OD 600 was monitored up to 15 h postinoculation to follow the influence of AMPs on culture growth. 
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
This work was supported by grants from the National Institutes of Health (American Recovery and Reinvestment Act Grant GM086865), the National Science Foundation (Grants CBET-0425882 and CBET-0644792), and the University of Minnesota Biotechnology Institute. K.V. was also supported by the University of Minnesota Dosdall Fellowship.
